Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Urol Video J. 2020 Jun 15;7:100047. doi: 10.1016/j.urolvj.2020.100047

Table 3.

Patients with Peyronie’s disease who were candidates for collagenase clostridium histolyticum treatment in the University of Miami Hospital, Department of Male Reproductive Medicine, in the period November 2018-December 2019.

Candidates for Collagenase Clostridium Histolyticum
Noncalcified Calcified p
N (%) 26 (28.3) 66 (71. 7)
Curvature (degrees) 46.1 ± 14.7 51.2 ± 17.6 0.17
Duration of symptoms
(months) 39.5 ± 61.2 22.6 ± 30.3 0.34